Sedation outcomes for remimazolam, a new benzodiazepine

Remimazolam is a new ultrashort-acting benzodiazepine with fast onset, quick recovery, and few side effects, such as hypotension respiratory depression. It expected to be safe effective for wide range of patients undergoing intravenous sedation dental procedures. The aim this literature review was evaluate clinical outcomes remimazolam, including method administration, level at the dose required, adverse events. An electronic search databases conducted, eight articles were selected inclusion in review. Onset time from drug administration optimal faster remimazolam (around 1.5-6.4 min) than midazolam. Recovery significantly shorter midazolam propofol. A study comparing various doses found no significant difference safety. Comparison group propofol showed that incidences (13.0% vs 42.9%, respectively) depression (1.1% 6.9%, lower remimazolam. appears an ideal sedative.